Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

George M. Milne Jr.

At a glance: George M. Milne Jr. is Director at Amylyx Pharmaceuticals (AMLX). Their latest SEC Form 4, filed Oct 7, 2026, reported a sale of $831K. On file: 0 purchase lines ($0) and 1 sale line ($831K).

Disclosed holdings: about $20.5M of AMLX stock: 782,881 shares reported on their latest Form 4 (filed Oct 7, 2026), valued at the Nov 20, 2026 close of $26.13. This counts only AMLX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Amylyx Pharmaceuticals, Inc. (AMLX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $831K

George M. Milne Jr.'s InsiderPrint

6 trades from SEC Form 4 filings, 2021 to 2026, drawn as one fingerprint.

InsiderPrint of George M. Milne Jr.: 6 trades, 2021 to 20262021: 1 buy, 0 sales2022: 2 buys, 0 sales2023: 1 buy, 0 sales2024: 1 buy, 0 sales2025: 0 buys, 0 sales2026: 0 buys, 1 sale

Reading this print: Mostly buys, trading about once a year, typically $220K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.

  • Bump outward: a purchase (5)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. John R. SultDirector · VST · 97% match
  2. Mark T. BehrmanCEO, President · LXU · 97% match
  3. Adrian T. DillonDirector · HQY · 95% match
  4. Andrew LabenneCFO · HAPN · 95% match
  5. Enrique LoresCEO, President · HPQ · 95% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2021

From the SEC's insider data sets: each open-market buy by George M. Milne Jr., matched to how the stock did over the next 90 days against the S&P 500.

1 of 3 buys beat the S&P 500 (33%), median -2.2% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
AUPHMar 6, 2023-2.2%
AUPHMar 11, 2022+18.0%
AUPHMar 9, 2021-11.2%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Oct 7SEC AMLXAmylyx Pharmaceuticals, Inc. Sell Plan 30,000782,881 held (−4%) $27.70 $831K -5.7%
  • Sell

    Director George M Milne Jr. sold $831K of AMLX at $27.70 — pre-scheduled 10b5-1 plan sale.

Follow George M. Milne Jr.

Get one email when George M. Milne Jr. files a new purchase or sale. Free.

At most one email a day about George M. Milne Jr., plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.